AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Inc. (NYSE American: AIM) has announced a conference call and webcast to discuss its Q2 2024 operational and financial results on Friday, August 16, 2024, at 8:30 AM ET. The call will be hosted by CEO Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Investors can access the call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international), referencing the AIM ImmunoTech Conference Call. The webcast will be available on the company's website, aimimmuno.com, in the Investors section's Events page and will be archived for 90 days after the event.
AIM ImmunoTech Inc. (NYSE American: AIM) ha annunciato una conference call e un webcast per discutere i risultati operativi e finanziari del Q2 2024 il venerdì 16 agosto 2024, alle 8:30 AM ET. La chiamata sarà condotta dal CEO Thomas K. Equels e dal Direttore Scientifico Christopher McAleer, PhD. Gli investitori possono accedere alla chiamata componendo (877) 407-9219 (domestica) o (201) 689-8852 (internazionale), facendo riferimento alla Conference Call di AIM ImmunoTech. Il webcast sarà disponibile sul sito web della società, aimimmuno.com, nella sezione Eventi della pagina per gli Investitori e sarà archiviato per 90 giorni dopo l'evento.
AIM ImmunoTech Inc. (NYSE American: AIM) ha anunciado una conferencia telefónica y un webcast para discutir sus resultados operativos y financieros del Q2 2024 el viernes 16 de agosto de 2024, a las 8:30 AM ET. La llamada será presentada por el CEO Thomas K. Equels y el Director Científico Christopher McAleer, PhD. Los inversores pueden acceder a la llamada marcando (877) 407-9219 (nacional) o (201) 689-8852 (internacional), haciendo referencia a la Conferencia Telefónica de AIM ImmunoTech. El webcast estará disponible en el sitio web de la empresa, aimimmuno.com, en la sección de Eventos para Inversionistas y estará archivado durante 90 días después del evento.
AIM ImmunoTech Inc. (NYSE American: AIM)는 2024년 2분기 운영 및 재무 결과에 대해 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 2024년 8월 16일 금요일 오전 8시 30분 ET에 발표한다고 발표했습니다. 이 콜은 CEO인 Thomas K. Equels와 과학 담당 Christopher McAleer, PhD가 진행할 것입니다. 투자자들은 (877) 407-9219 (국내) 또는 (201) 689-8852 (국제)로 전화하여 AIM ImmunoTech 컨퍼런스 콜을 참조하여 접속할 수 있습니다. 웹캐스트는 회사 웹사이트 aimimmuno.com의 투자자 섹션 이벤트 페이지에서 이용 가능하며, 이벤트 후 90일 동안 아카이빙됩니다.
AIM ImmunoTech Inc. (NYSE American: AIM) a annoncé une conférence téléphonique et un webcast pour discuter de ses résultats opérationnels et financiers du Q2 2024 le vendredi 16 août 2024, à 8h30 ET. L'appel sera animé par le PDG Thomas K. Equels et le Directeur Scientifique Christopher McAleer, PhD. Les investisseurs peuvent accéder à l'appel en composant le (877) 407-9219 (national) ou le (201) 689-8852 (international), en se référant à la Conférence Téléphonique d'AIM ImmunoTech. Le webcast sera disponible sur le site web de l'entreprise, aimimmuno.com, dans la section Événements des Investisseurs et sera archivé pendant 90 jours après l'événement.
AIM ImmunoTech Inc. (NYSE American: AIM) hat eine Telefonkonferenz und ein Webcast angekündigt, um über die betrieblichen und finanziellen Ergebnisse des Q2 2024 zu sprechen, und zwar am Freitag, den 16. August 2024, um 8:30 Uhr ET. Die Moderation übernehmen CEO Thomas K. Equels und der wissenschaftliche Leiter Christopher McAleer, PhD. Investoren können die Konferenz unter (877) 407-9219 (national) oder (201) 689-8852 (international) erreichen, indem sie auf die AIM ImmunoTech Telefonkonferenz verweisen. Das Webcast wird auf der Unternehmenswebsite aimimmuno.com im Bereich Veranstaltungen unter Investoren verfügbar sein und 90 Tage nach der Veranstaltung archiviert.
- None.
- None.
OCALA, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q2 2024 operational and financial results on Friday, August 16, 2024 at 8:30 AM ET.
The call will be hosted by AIM’s Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com, and will be archived for 90 days following the live event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
FAQ
When will AIM ImmunoTech (AIM) report its Q2 2024 financial results?
How can investors access AIM ImmunoTech's Q2 2024 earnings call?
Where can I find the webcast for AIM ImmunoTech's Q2 2024 earnings call?
Who will host AIM ImmunoTech's Q2 2024 earnings call?
